New combo therapy aims to keep hepatitis b in check
Disease control
Not yet recruiting
This phase 3 trial tests a new drug called GST-HG141 (Nairecovir) combined with standard antivirals in 576 adults with chronic hepatitis B. Participants have already completed 48 weeks of treatment in an earlier study. The goal is to see if the combination is safe and helps keep …
Phase: PHASE3 • Sponsor: Fujian Akeylink Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC